Cara Therapeutics to Participate in October Medical Meetings

Edit Stockhouse 12 Oct 2016
STAMFORD, Conn., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq.CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced its participation at two upcoming medical meetings, both of which will be held in Chicago ... CT ... Panelists. ... CT ... pentazocine, a Schedule IV analgesic ... ....

Cara Therapeutics to Participate in October Medical Meetings (CARA Therapeutics Inc)

Edit Public Technologies 12 Oct 2016
(Source. CARA Therapeutics Inc). STAMFORD, Conn., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... At the 10 Annual Pain & Migraine Therapeutics Summit (to be held October 19-20, 2016), Dr. Joseph Stauffer, Cara's Chief Medical Officer, will speak on an expert panel and deliver a presentation on kappa opioid receptor agonists (KORAs) as a novel approach to acute and chronic pain management ... CT ... pentazocine, a Schedule IV analgesic....

Cara Therapeutics to Host Industry Symposium at the Orthopaedic Trauma Association 2016 Annual Meeting

Edit Stockhouse 29 Sep 2016
STAMFORD, Conn., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... The findings to be presented support the view that CR845 is unlikely to be recreationally abused or lead to physical dependence. The symposium details are as follows. . Date.  Thursday, October 6, 2016. Time.  11.45 a.m. – 12.45 p.m. ET. Location ... Moderator ... Faculty.  Hassan R ... About CR845 ... pentazocine, a Schedule IV analgesic ... About Cara Therapeutics ... ....

Cara Therapeutics to Host Industry Symposium at the Orthopaedic Trauma Association 2016 Annual Meeting (CARA Therapeutics Inc)

Edit Public Technologies 29 Sep 2016
(Source. CARA Therapeutics Inc). STAMFORD, Conn., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... The findings to be presented support the view that CR845 is unlikely to be recreationally abused or lead to physical dependence. The symposium details are as follows.. Date. Thursday, October 6, 2016. Time. 11.45 a.m. - 12.45 p.m. ET. Location ... Moderator ... Faculty. Hassan R ... About CR845 ... pentazocine, a Schedule IV analgesic ... INVESTOR CONTACT....

Cara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral ...

Edit Stockhouse 15 Sep 2016
The primary objective of the trial was to measure the relative abuse potential of both a therapeutic and supratherapeutic dose of CR845, compared to an intravenous dose of pentazocine ... pentazocine, a Schedule IV opioid receptor agonist ... CR845 also demonstrated highly statistically significant lower “feeling high” and “overall liking” scores (p <0.0001) as compared to pentazocine....

Cara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients (CARA Therapeutics Inc)

Edit Public Technologies 15 Sep 2016
The primary objective of the trial was to measure the relative abuse potential of both a therapeutic and supratherapeutic dose of CR845, compared to an intravenous dose of pentazocine. Pentazocine is a mixed-action kappa and mu opioid receptor agonist used clinically in the treatment of moderate-to-severe pain and is classified by the Drug ......

Cara Therapeutics to Sponsor Symposium and Present Posters at PAINWeek

Edit Stockhouse 01 Sep 2016
Pain experts to discuss developments in kappa opioid receptor agonists and the future of pain management. Company to present data from Phase 2 chronic osteoarthritis pain and human abuse liability trials of CR845 in poster sessions. STAMFORD, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... The symposium details are as follows.&nbsp;. Date. Friday, September 9, 2016. Time ... PT. Location ... PT ... pentazocine, a Schedule IV analgesic....

Cara Therapeutics to Sponsor Symposium and Present Posters at PAINWeek (CARA Therapeutics Inc)

Edit Public Technologies 01 Sep 2016
(Source. CARA Therapeutics Inc) Pain experts to discuss developments in kappa opioid receptor agonists and the future of pain management. Company to present data from Phase 2 chronic osteoarthritis pain and human abuse liability trials of CR845 in poster sessions. STAMFORD, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... The symposium details are as follows.. Date ... Time ... PT. Location ... PT ... pentazocine, a Schedule IV analgesic....

Cara Therapeutics' Data to be Presented at the British Association for Psychopharmacology 2016 Summer Meeting (CARA Therapeutics Inc)

Edit Public Technologies 13 Jul 2016
(Source. CARA Therapeutics Inc). STAMFORD, Conn., July 13, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... Professor David J. Heal, Ph.D., D.Sc., F.R.C.S., Executive Director at RenaSci, Ltd., will present preclinical data on aspects of CR845's potential for abuse. The findings to be presented support the view that CR845 is unlikely to be recreationally abused or liable to cause physical dependence ... pentazocine, a Schedule IV analgesic....

Cara Therapeutics to Present Preclinical Data at June Medical Meetings (CARA Therapeutics Inc)

Edit Public Technologies 09 Jun 2016
(Source. CARA Therapeutics Inc). STAMFORD, Conn., June 09, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... Professor David J ... Details of the presentations are as follows.. International Study Group Investigating Drugs as Reinforcers (ISGIDAR). Title ... 'Investigation of the κ-opioid receptor agonist CR845 and reference comparator, butorphanol, in rats trained to discriminate (-) pentazocine from saline' ... pentazocine, a Schedule IV analgesic....

Cara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain (CARA Therapeutics Inc)

Edit Public Technologies 06 Jun 2016
(Source. CARA Therapeutics Inc). STAMFORD, Conn., June 06, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ.CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has resumed patient recruitment after the U.S ... About CR845 ... pentazocine, a Schedule IV analgesic ... Source....

Cara Therapeutics Selected to Present at the 2016 International Conference on Opioids (CARA Therapeutics Inc)

Edit Public Technologies 31 May 2016
(Source. CARA Therapeutics Inc) Leading experts to discuss unique pharmacology of peripherally selective opioids to manage chronic and acute pain during opening session. Company to present positive data from Phase 2a study of Oral CR845 in chronic pain patients. STAMFORD, Conn., May 31, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... CR845 ... Details of the presentation are as follows.. Date ... Time ... ET ... ET ... pentazocine, a Schedule IV analgesic....

Cara Therapeutics to Sponsor Symposium at American Pain Society 35th Annual Scientific Meeting (CARA Therapeutics Inc)

Edit Public Technologies 05 May 2016
(Source. CARA Therapeutics Inc) Pain experts to discuss kappa opioid receptor agonists as alternative to standard mu opioid agonists. SHELTON, Conn., May 04, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc ... Leaving the Baggage Behind' in two sessions at the American Pain Society's 35 Annual Scientific Meeting, to be held May 11-14, 2016 in Austin, Texas ... The Town Hall Talk details are as follows. ... CT ... pentazocine, a Schedule IV analgesic....
×